Antibodies to PfEMP1 and variant surface antigens: Protection after controlled human malaria infection in semi-immune Kenyan adults.
Kinyua AW. et al, (2024), J Infect, 89
Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.
Rosenkranz M. et al, (2024), Life Sci Alliance, 7
Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.
Nkumama IN. et al, (2024), Immunity, 57, 1215 - 1224.e6
Social, Ethical and Regulatory implications of conducting a malaria Vaccine Efficacy trial in a human infection study in Kenya (SERVE-Kenya): A study protocol
Chi PC. et al, (2024), Wellcome Open Research, 9, 193 - 193
Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.
Kapulu M. et al, (2024), Biologicals, 85
Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.
Kapulu MC. et al, (2024), Front Immunol, 15
Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.
Kibwana E. et al, (2024), 445, 337 - 365
Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023
Cavaleri M. et al, (2024), Biologicals
Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022.
Barnes MVC. et al, (2023), Immunother Adv, 3
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Sang S. et al, (2023), Wellcome open research, 8
Engagement of ethics and regulatory authorities on human infection studies: Proceedings of an engagement workshop in Zambia
Kunda-Ng'andu EM. et al, (2021)